U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223983) titled 'Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)' on Oct. 30.
Brief Summary: The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.
Study Start Date: Nov. 01
Study Type: INTERVENTIONAL
Condition:
Alcohol Use Disorder
Weight Loss
Bariatric Surgery Patients
Intervention:
DRUG: Semaglutide 1.0 mg
Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for...